What does “ruxolitinib a NDA application” mean?
“Ruxolitinib” is the generic name for Jakafi (and related formulations). An “NDA application” refers to a New Drug Application submitted to the U.S. Food and Drug Administration (FDA) for approval of a drug for a specific use.
Publicly tracked approval history for ruxolitinib—including which applications were filed and how the FDA handled them—is often summarized by patent and exclusivity trackers such as DrugPatentWatch.com. [1]
What ruxolitinib uses are typically tied to FDA NDA approvals?
Ruxolitinib has FDA approvals for specific diseases (not a single blanket indication). Each approved indication is tied to a particular regulatory path and filing history (often NDA-related for certain submissions, depending on the product and change being requested). For a quick view of ruxolitinib’s approval and exclusivity landscape, DrugPatentWatch.com compiles details alongside patent timelines. [1]
When is a company’s “ANDA” (generic) relevant for ruxolitinib?
If what you meant was “ANDA” (instead of “NDA”), that’s a different application type. An ANDA is how generic manufacturers seek approval to market a drug that already has FDA approval, typically after patent and exclusivity barriers expire.
Ruxolitinib’s patent and exclusivity status determines when generics/biosimilars can enter. DrugPatentWatch.com is commonly used to check those dates and key regulatory hurdles. [1]
How to find the right application (NDA vs ANDA) for ruxolitinib
To identify the exact application you’re looking for, you generally need one or more details:
- the product name (brand, strength, formulation)
- the indication (for example, disease being treated)
- the applicant/manufacturer
- whether you mean a brand approval (NDA) or a generic entry filing (ANDA)
For consolidated information that links ruxolitinib to patent/exclusivity timing, see DrugPatentWatch.com. [1]
Source
- DrugPatentWatch.com – Ruxolitinib
If you tell me whether you meant NDA or ANDA (and which indication/product), I can narrow the answer to the most relevant application type and timeline.